NCT06849219View on ClinicalTrials.gov

Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

September 21, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

March 21, 2025

Conditions
Trigeminal Neuralgia
Interventions
DRUG

Oxcarbazepine

Oxcarbazepine will be started at a dose of 150 mg BD, and follow-up will be done every month. Dose will be titrated up if minimal pain relief, to a maximum dose of 1800 mg per day.

DRUG

Carbamazepine

Carbamazepine will be started at a dose of 100 mg BD, and follow-up will be done every month. Dose will be titrated up if minimal pain relief, to a maximum dose of 1200 mg per day.

Trial Locations (1)

75510

Jinnah Postgraduate Medical Centre, Karachi

All Listed Sponsors
lead

Jinnah Postgraduate Medical Centre

OTHER_GOV

NCT06849219 - Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia | Biotech Hunter | Biotech Hunter